Phase II crinical trial of cetuximab rechallenge with KRAS wild-type unresectable/recurrent colorectal cancer
Not Applicable
- Conditions
- Colorectal cancer
- Registration Number
- JPRN-UMIN000009698
- Lead Sponsor
- Okayama Molecular Target-Based Drugs Society for Cancer of the Colon and Rectum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1)Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ 2)Patients with brain metastasis which have symptoms or patients with history of brain metastasis 3)Severe wattery diarrhea 4)Severe infectious disease 5)Severe complications (interstitial lung disease or pulmonary fibrosis, kidney failure, hepatic failure, uncontrolable diabetes, uncontrolable hypertension) 6)Severe carcinomatous ascites, pleural effusion or pericardial cavity effusion 7)Pregnant or lactating women or women of childbearing potential, and no birth-control 8)Patients with history of serious hypersensitivity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate(RR)
- Secondary Outcome Measures
Name Time Method Progression free survival(PFS) Overall survival(OS) Safety